SCHOTT PHARMA AG& CO KGAA (1SXP.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:1SXP - DE000A3ENQ51 - Common Stock
15.02 EUR
-0.08 (-0.53%)
Overall 1SXP gets a fundamental rating of 6 out of 10. We evaluated 1SXP against 22 industry peers in the Life Sciences Tools & Services industry. 1SXP scores excellent on profitability, but there are some minor concerns on its financial health. 1SXP has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
- In the past year 1SXP was profitable.
- In the past year 1SXP had a positive cash flow from operations.
- Each year in the past 5 years 1SXP has been profitable.
- In the past 5 years 1SXP always reported a positive cash flow from operatings.
1.2 Ratios
- The Return On Assets of 1SXP (9.16%) is better than 86.36% of its industry peers.
- With an excellent Return On Equity value of 16.42%, 1SXP belongs to the best of the industry, outperforming 86.36% of the companies in the same industry.
- With an excellent Return On Invested Capital value of 13.06%, 1SXP belongs to the best of the industry, outperforming 86.36% of the companies in the same industry.
- 1SXP had an Average Return On Invested Capital over the past 3 years of 14.59%. This is significantly above the industry average of 9.34%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.16% | ||
| ROE | 16.42% | ||
| ROIC | 13.06% |
ROA(3y)10.63%
ROA(5y)11.2%
ROE(3y)19.15%
ROE(5y)19.86%
ROIC(3y)14.59%
ROIC(5y)15.53%
1.3 Margins
- 1SXP has a better Profit Margin (14.85%) than 77.27% of its industry peers.
- In the last couple of years the Profit Margin of 1SXP has grown nicely.
- 1SXP has a Operating Margin of 18.95%. This is in the better half of the industry: 1SXP outperforms 72.73% of its industry peers.
- In the last couple of years the Operating Margin of 1SXP has grown nicely.
- 1SXP has a Gross Margin of 33.71%. This is in the lower half of the industry: 1SXP underperforms 63.64% of its industry peers.
- 1SXP's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 18.95% | ||
| PM (TTM) | 14.85% | ||
| GM | 33.71% |
OM growth 3Y-2.54%
OM growth 5Y4%
PM growth 3Y-0.93%
PM growth 5Y2.28%
GM growth 3Y-2.25%
GM growth 5Y0.1%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), 1SXP is creating some value.
- 1SXP has about the same amout of shares outstanding than it did 1 year ago.
- The number of shares outstanding for 1SXP remains at a similar level compared to 5 years ago.
- 1SXP has a better debt/assets ratio than last year.
2.2 Solvency
- The Debt to FCF ratio of 1SXP is 2.43, which is a good value as it means it would take 1SXP, 2.43 years of fcf income to pay off all of its debts.
- With an excellent Debt to FCF ratio value of 2.43, 1SXP belongs to the best of the industry, outperforming 90.91% of the companies in the same industry.
- A Debt/Equity ratio of 0.09 indicates that 1SXP is not too dependend on debt financing.
- The Debt to Equity ratio of 1SXP (0.09) is better than 95.45% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 2.43 | ||
| Altman-Z | N/A |
ROIC/WACC1.45
WACC9%
2.3 Liquidity
- 1SXP has a Current Ratio of 1.50. This is a normal value and indicates that 1SXP is financially healthy and should not expect problems in meeting its short term obligations.
- 1SXP has a Current ratio of 1.50. This is in the better half of the industry: 1SXP outperforms 68.18% of its industry peers.
- 1SXP has a Quick Ratio of 1.12. This is a normal value and indicates that 1SXP is financially healthy and should not expect problems in meeting its short term obligations.
- 1SXP's Quick ratio of 1.12 is fine compared to the rest of the industry. 1SXP outperforms 68.18% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.5 | ||
| Quick Ratio | 1.12 |
3. Growth
3.1 Past
- 1SXP shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -2.02%.
- Measured over the past years, 1SXP shows a quite strong growth in Earnings Per Share. The EPS has been growing by 13.78% on average per year.
- 1SXP shows a small growth in Revenue. In the last year, the Revenue has grown by 3.04%.
- The Revenue has been growing by 11.04% on average over the past years. This is quite good.
EPS 1Y (TTM)-2.02%
EPS 3Y5.42%
EPS 5Y13.78%
EPS Q2Q%0%
Revenue 1Y (TTM)3.04%
Revenue growth 3Y6.3%
Revenue growth 5Y11.04%
Sales Q2Q%4.44%
3.2 Future
- Based on estimates for the next years, 1SXP will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.98% on average per year.
- Based on estimates for the next years, 1SXP will show a small growth in Revenue. The Revenue will grow by 7.13% on average per year.
EPS Next Y5.75%
EPS Next 2Y11.1%
EPS Next 3Y11.63%
EPS Next 5Y12.98%
Revenue Next Year4.39%
Revenue Next 2Y6.84%
Revenue Next 3Y6.72%
Revenue Next 5Y7.13%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 15.48, the valuation of 1SXP can be described as correct.
- Based on the Price/Earnings ratio, 1SXP is valued cheaply inside the industry as 90.91% of the companies are valued more expensively.
- 1SXP is valuated rather cheaply when we compare the Price/Earnings ratio to 27.54, which is the current average of the S&P500 Index.
- Based on the Price/Forward Earnings ratio of 14.64, the valuation of 1SXP can be described as correct.
- Based on the Price/Forward Earnings ratio, 1SXP is valued cheaper than 90.91% of the companies in the same industry.
- 1SXP's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 24.31.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.48 | ||
| Fwd PE | 14.64 |
4.2 Price Multiples
- 90.91% of the companies in the same industry are more expensive than 1SXP, based on the Enterprise Value to EBITDA ratio.
- Based on the Price/Free Cash Flow ratio, 1SXP is valued a bit more expensive than 68.18% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 64.33 | ||
| EV/EBITDA | 8.69 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates 1SXP does not grow enough to justify the current Price/Earnings ratio.
- The excellent profitability rating of 1SXP may justify a higher PE ratio.
PEG (NY)2.7
PEG (5Y)1.12
EPS Next 2Y11.1%
EPS Next 3Y11.63%
5. Dividend
5.1 Amount
- 1SXP has a Yearly Dividend Yield of 1.18%. Purely for dividend investing, there may be better candidates out there.
- The stock price of 1SXP dropped by -24.52% in the last 3 months. With lower prices the dividend yield is higher, but it may be a sign investors do not trust the long term dividend.
- 1SXP's Dividend Yield is rather good when compared to the industry average which is at 0.54. 1SXP pays more dividend than 90.91% of the companies in the same industry.
- 1SXP's Dividend Yield is slightly below the S&P500 average, which is at 1.92.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.18% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years1
Div Non Decr Years1
5.3 Sustainability
- 16.45% of the earnings are spent on dividend by 1SXP. This is a low number and sustainable payout ratio.
DP16.45%
EPS Next 2Y11.1%
EPS Next 3Y11.63%
FRA:1SXP (1/15/2026, 7:00:00 PM)
15.02
-0.08 (-0.53%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)12-11 2025-12-11/amc
Earnings (Next)02-11 2026-02-11
Inst Owners22.72%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap2.26B
Revenue(TTM)986.21M
Net Income(TTM)146.45M
Analysts75.79
Price Target23.9 (59.12%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.18% |
Yearly Dividend0.16
Dividend Growth(5Y)N/A
DP16.45%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-2.27%
Min EPS beat(2)-3.5%
Max EPS beat(2)-1.05%
EPS beat(4)1
Avg EPS beat(4)-3.37%
Min EPS beat(4)-14.42%
Max EPS beat(4)5.48%
EPS beat(8)3
Avg EPS beat(8)1.1%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-2.13%
Min Revenue beat(2)-2.27%
Max Revenue beat(2)-1.99%
Revenue beat(4)1
Avg Revenue beat(4)-1.96%
Min Revenue beat(4)-5.31%
Max Revenue beat(4)1.75%
Revenue beat(8)3
Avg Revenue beat(8)0.96%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-16.41%
PT rev (3m)-20.68%
EPS NQ rev (1m)-6.61%
EPS NQ rev (3m)-14.29%
EPS NY rev (1m)-10.89%
EPS NY rev (3m)-15.27%
Revenue NQ rev (1m)-3.21%
Revenue NQ rev (3m)-5.48%
Revenue NY rev (1m)-4.21%
Revenue NY rev (3m)-5.42%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.48 | ||
| Fwd PE | 14.64 | ||
| P/S | 2.29 | ||
| P/FCF | 64.33 | ||
| P/OCF | 12.57 | ||
| P/B | 2.54 | ||
| P/tB | 2.62 | ||
| EV/EBITDA | 8.69 |
EPS(TTM)0.97
EY6.46%
EPS(NY)1.03
Fwd EY6.83%
FCF(TTM)0.23
FCFY1.55%
OCF(TTM)1.19
OCFY7.95%
SpS6.55
BVpS5.92
TBVpS5.72
PEG (NY)2.7
PEG (5Y)1.12
Graham Number11.37
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.16% | ||
| ROE | 16.42% | ||
| ROCE | 16.33% | ||
| ROIC | 13.06% | ||
| ROICexc | 13.46% | ||
| ROICexgc | 13.83% | ||
| OM | 18.95% | ||
| PM (TTM) | 14.85% | ||
| GM | 33.71% | ||
| FCFM | 3.57% |
ROA(3y)10.63%
ROA(5y)11.2%
ROE(3y)19.15%
ROE(5y)19.86%
ROIC(3y)14.59%
ROIC(5y)15.53%
ROICexc(3y)15.01%
ROICexc(5y)16.12%
ROICexgc(3y)15.5%
ROICexgc(5y)16.82%
ROCE(3y)18.26%
ROCE(5y)19.44%
ROICexgc growth 3Y-6.05%
ROICexgc growth 5Y-8.67%
ROICexc growth 3Y-5.65%
ROICexc growth 5Y-7.55%
OM growth 3Y-2.54%
OM growth 5Y4%
PM growth 3Y-0.93%
PM growth 5Y2.28%
GM growth 3Y-2.25%
GM growth 5Y0.1%
F-Score6
Asset Turnover0.62
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 2.43 | ||
| Debt/EBITDA | 0.3 | ||
| Cap/Depr | 182.22% | ||
| Cap/Sales | 14.68% | ||
| Interest Coverage | 11.84 | ||
| Cash Conversion | 67.54% | ||
| Profit Quality | 24.01% | ||
| Current Ratio | 1.5 | ||
| Quick Ratio | 1.12 | ||
| Altman-Z | N/A |
F-Score6
WACC9%
ROIC/WACC1.45
Cap/Depr(3y)260.7%
Cap/Depr(5y)265.72%
Cap/Sales(3y)16.46%
Cap/Sales(5y)16.64%
Profit Quality(3y)27.05%
Profit Quality(5y)27.58%
High Growth Momentum
Growth
EPS 1Y (TTM)-2.02%
EPS 3Y5.42%
EPS 5Y13.78%
EPS Q2Q%0%
EPS Next Y5.75%
EPS Next 2Y11.1%
EPS Next 3Y11.63%
EPS Next 5Y12.98%
Revenue 1Y (TTM)3.04%
Revenue growth 3Y6.3%
Revenue growth 5Y11.04%
Sales Q2Q%4.44%
Revenue Next Year4.39%
Revenue Next 2Y6.84%
Revenue Next 3Y6.72%
Revenue Next 5Y7.13%
EBIT growth 1Y5.25%
EBIT growth 3Y3.6%
EBIT growth 5Y15.48%
EBIT Next Year43.48%
EBIT Next 3Y20.64%
EBIT Next 5Y16.53%
FCF growth 1Y-55.75%
FCF growth 3Y6.15%
FCF growth 5Y12.98%
OCF growth 1Y-19.95%
OCF growth 3Y-0.4%
OCF growth 5Y11.5%
SCHOTT PHARMA AG& CO KGAA / 1SXP.DE FAQ
Can you provide the ChartMill fundamental rating for SCHOTT PHARMA AG& CO KGAA?
ChartMill assigns a fundamental rating of 6 / 10 to 1SXP.DE.
What is the valuation status for 1SXP stock?
ChartMill assigns a valuation rating of 5 / 10 to SCHOTT PHARMA AG& CO KGAA (1SXP.DE). This can be considered as Fairly Valued.
How profitable is SCHOTT PHARMA AG& CO KGAA (1SXP.DE) stock?
SCHOTT PHARMA AG& CO KGAA (1SXP.DE) has a profitability rating of 8 / 10.
Can you provide the financial health for 1SXP stock?
The financial health rating of SCHOTT PHARMA AG& CO KGAA (1SXP.DE) is 6 / 10.
What is the earnings growth outlook for SCHOTT PHARMA AG& CO KGAA?
The Earnings per Share (EPS) of SCHOTT PHARMA AG& CO KGAA (1SXP.DE) is expected to grow by 5.75% in the next year.